Dylan Dupuis
Stock Analyst at Roth MKM
(2.78)
# 1,947
Out of 4,966 analysts
8
Total ratings
50%
Success rate
43.19%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dylan Dupuis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMMB Chemomab Therapeutics | Reinstates: Buy | $28 | $3.14 | +791.72% | 2 | Dec 19, 2023 | |
| IVA Inventiva | Reiterates: Buy | $11 | $6.19 | +77.71% | 2 | Sep 21, 2023 | |
| TERN Terns Pharmaceuticals | Reiterates: Buy | $23 | $6.96 | +230.46% | 3 | Aug 8, 2023 | |
| VKTX Viking Therapeutics | Assumes: Buy | $32 | $27.05 | +18.30% | 1 | May 31, 2023 |
Chemomab Therapeutics
Dec 19, 2023
Reinstates: Buy
Price Target: $28
Current: $3.14
Upside: +791.72%
Inventiva
Sep 21, 2023
Reiterates: Buy
Price Target: $11
Current: $6.19
Upside: +77.71%
Terns Pharmaceuticals
Aug 8, 2023
Reiterates: Buy
Price Target: $23
Current: $6.96
Upside: +230.46%
Viking Therapeutics
May 31, 2023
Assumes: Buy
Price Target: $32
Current: $27.05
Upside: +18.30%